Entrada shares slide as FDA maintains freeze on Duchenne drug

Entrada Therapeutics Inc. won't be able to start testing a Duchenne drug in the U.S. anytime soon, based on new feedback from the Food and Drug Administration.

Previous Health care technology company to lay off 99 employees in Hunt Valley
Next Penn spinout Vivodyne raises $38M to advance platform making lab-grown human organs for new drug testing